FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:456 August 5, 1999 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Parkinson Study Group PubMed Citation

To the Editor: The article by the Parkinson Study Group (March 11 issue)¹ and the accompanying editorial by Cummings² emphasize the potential benefits of clozapine for patients with psychosis resulting from medications used to treat Parkinson's disease. However, patients with Parkinson's disease may be at particular risk for one of the most serious complications of clozapine therapy: the neuroleptic malignant syndrome. Not mentioned in either the article or the editorial is the fact that the antipsychotic efficacy of clozapine in patients with schizophrenia is probably due in part to the glutamate-agonist activity of clozapine at N-methyl-d-aspartate receptors. The neuroleptic . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.